RET/PTC Oncogene Activation is an Early Event in Thyroid Carcinogenesis

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 1995 Sep 21

PMID 7566982

Citations 55

Authors

G Viglietto

G Chiappetta

F J Martinez-Tello

F H FUKUNAGA

G Tallini

D Rigopoulou

R Visconti

A Mastro

M Santoro

A Fusco

Affiliations

Soon will be listed here.

Abstract

RET/PTC oncogene activation occurs in about 20% of human thyroid papillary carcinomas. However, it is not known yet whether it is an early or late event in the process of thyroid carcinogenesis. Here we demonstrate, by using a combined immunohistochemical and reverse transcriptase-polymerase chain reaction based approach, that RET/PTC activation is present in 11 out of 26 occult thyroid papillary carcinomas analysed. Therefore, we conclude that it represents an early event in the process of thyroid cell transformation.

Citing Articles

Mechanisms of resistance to RET-directed therapies.

Clifton-Bligh R Endocr Relat Cancer. 2024; 32(2).

PMID: 39655713 PMC: 11798414. DOI: 10.1530/ERC-24-0224.

Effective Preparation of FFPE Tissue Samples for Preserving Appropriate Nucleic Acid Quality for Genomic Analysis in Thyroid Carcinoma.

Okubo Y, Toyama N, Kasajima R, Toda S, Hayashi H, Yoshioka E Endocr Pathol. 2024; 35(4):372-384.

PMID: 39560912 PMC: 11659341. DOI: 10.1007/s12022-024-09838-9.

RET signaling pathway and RET inhibitors in human cancer.

Regua A, Najjar M, Lo H Front Oncol. 2022; 12:932353.

PMID: 35957881 PMC: 9359433. DOI: 10.3389/fonc.2022.932353.

The contribution of molecular pathology to the classification of thyroid tumors.

Xu B, Ghossein R Diagn Histopathol (Oxf). 2021; 24(3):87-94.

PMID: 34017360 PMC: 8133694. DOI: 10.1016/j.mpdhp.2018.02.001.

Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.

Gattelli A, Hynes N, Schor I, Vallone S J Mammary Gland Biol Neoplasia. 2020; 25(1):13-26.

PMID: 32080788 DOI: 10.1007/s10911-020-09445-4.